De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Xvivo Perfusion Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Xvivo Perfusion heeft een totaal eigen vermogen van SEK2.0B en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK2.3B en SEK248.2M. De EBIT Xvivo Perfusion is SEK42.8M waardoor de rentedekking -47.7 is. Het heeft contanten en kortetermijnbeleggingen van SEK480.8M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	-47.7x
Contant	SEK 480.77m
Aandelen	SEK 2.02b
Totaal verplichtingen	SEK 248.19m
Totaal activa	SEK 2.27b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK830.1M ) XVIVO } overtreffen de korte termijn passiva ( SEK201.0M ).

Langlopende schulden: De kortetermijnactiva XVIVO ( SEK830.1M ) overtreffen de langetermijnschulden ( SEK47.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: XVIVO is schuldenvrij.

Schuld verminderen: XVIVO heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 1.3% was.

Schuldendekking: XVIVO heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: XVIVO heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Xvivo Perfusion Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.1% to kr450

Consensus EPS estimates increase by 10%

Now 20% undervalued

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%

Xvivo Perfusion AB (Publ) Presents Positive Results from the Australian & New Zealand Heart Preservation Study

Consensus EPS estimates increase by 14%

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Chairman of the Board recently bought kr201k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces CEO Changes

XVIVO Perfusion AB Receives Breakthrough Device Designation Grant from the FDA for the Liver Assist Device

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Xvivo Perfusion AB (publ) (OM:XVIVO) signed an agreement to acquire Machine and perfusion business from Avionord Srl for €12 million.

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

President & CEO exercised options to buy kr1.3m worth of stock.

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations